For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Teduglutide
Illustration for Teduglutide

THE PEPSRADAR ENCYCLOPEDIA

Teduglutide

GLP-2-related intestinal absorption

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Teduglutide · KEY FACTS

Content updated · how dates work

Saved peptides

Half-life source: FDA label (Gattex) on DailyMed ↗

What is Teduglutide?

Teduglutide is a peptide medicine for short bowel syndrome with dependence on intravenous nutrition or fluids. It acts in a different pathway from GLP-1 medicines.

Biological role or research focus

GLP-2-related intestinal absorption.

Its short bowel syndrome context is different from GLP-1 appetite medicines.

Role reference: MedlinePlus · Teduglutide ↗

Names you may encounter

Gattex

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
GLP-2 analogue
Main research area
Intestinal absorption in short bowel syndrome
Evidence featured
Human randomized trial
Source check
October 4, 2026

Source: MedlinePlus · Teduglutide ↗

Quick answers

Is Teduglutide FDA approved?
Yes. Gattex (NDA 203441, approved December 2012) for short bowel syndrome in patients dependent on parenteral support. Source ↗
Is Teduglutide safe?
Teduglutide is a GLP-2 drug for short bowel syndrome; because it makes gut tissue grow, its label warns of polyps and tumor growth, bowel blockage, gallbladder and pancreas disease and fluid overload. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Teduglutide banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
STEPS (2012)Human randomized trial86 patients with short bowel syndrome and intestinal failure requiring parenteral support.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2012

STEPS

Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.

Population / model
86 patients with short bowel syndrome and intestinal failure requiring parenteral support.
Study design
Twenty-four-week placebo-controlled study with protocol-guided support reductions.
Main finding
A reduction of more than 20% in support volume at weeks 20 and 24 occurred in 63% versus 30%. Mean weekly volume reduction was 4.4 versus 2.3 liters.
Limits & context
A response did not necessarily mean complete independence from IV support. The outcome is specific to intestinal failure, not general gut symptoms or appetite control.

Source: Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

48 registered studies name Teduglutide as an intervention; 3 are recruiting or under way, 1 has not started recruiting yet, 41 completed and 3 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)
NCT05561647 · Takeda
Completed2013-08-01600
A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
NCT06973304 · Takeda
Active, not recruitingPhase 32025-06-2613
A Study of Teduglutide in Japanese People With Short Bowel Syndrome
NCT05023382 · Takeda
Completed2021-09-01250
Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunction (EED)
NCT07537686 · International Centre for Diarrhoeal Disease Research, Bangladesh
Not yet recruitingPhase 22026-07-0155
A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome
NCT07319832 · Takeda
Recruiting2026-03-0512
TED_ORG: Study on Short Bowel Syndrome
NCT07400783 · Meyer Children's Hospital IRCCS
RecruitingNot applicable2024-10-3050
Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients
NCT03562130 · Assistance Publique - Hôpitaux de Paris
CompletedPhase 42018-07-0225
A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada
NCT05371028 · Takeda
Completed2023-09-2352

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 48 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Definition, classification, and causes of short bowel syndrome. ↗
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2023 May · Journal Article, Review

Understanding short bowel syndrome: Current status and future perspectives. ↗
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2020 Mar · Journal Article, Review

Updates in Intestinal Failure Management. ↗
Journal of clinical medicine · 2025 Apr 28 · Journal Article, Review
Read available full text ↗

Teduglutide. ↗
· 2006 · Review

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Teduglutide is a GLP-2 drug for short bowel syndrome; because it makes gut tissue grow, its label warns of polyps and tumor growth, bowel blockage, gallbladder and pancreas disease and fluid overload.

Human safety data: FDA label

Safety is established by FDA labeling. Tumors appeared in rat and mouse cancer studies and polyps were seen in patients, so the label calls for regular colonoscopy checks. The label lists no contraindications; breastfeeding is not recommended.

Take extra care with: Heart or blood pressure problemsCancer, now or in the past

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Interactions

  • Oral medicines, especially benzodiazepines or narrow-margin drugs: absorption may increase, raising side effects

Serious risks

  • Faster growth of existing tumors, and intestinal polyps
  • Intestinal or stoma blockage
  • Gallbladder, bile duct and pancreas disease
  • Fluid overload, including heart failure

Common side effects

  • abdominal pain
  • nausea
  • upper respiratory infections
  • abdominal bloating
  • injection-site reactions
  • vomiting
  • fluid overload
  • allergic reactions

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Gattex (teduglutide) prescribing information ↗

Key precautions

Intestinal polyps or malignancy history, obstruction symptoms, fluid overload, and gallbladder or pancreatic problems affect monitoring. Better absorption can also change exposure to oral medicines.

Source: MedlinePlus · Teduglutide ↗

Regulatory status

U.S. FDA approval
Approved
Gattex (NDA 203441, approved December 2012) for short bowel syndrome in patients dependent on parenteral support. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical uses & product context

Its medication reference describes short bowel syndrome requiring supplemental IV support. The study below evaluates a reduction in that support, not general gut comfort or weight loss.

Source: MedlinePlus · Teduglutide ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.

Mechanism & research rationale

It promotes intestinal absorptive capacity. The key clinical question is whether patients can safely reduce the amount or frequency of parenteral support.

Source: MedlinePlus · Teduglutide ↗

Molecular structure

Teduglutide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 16139605 ↗

Questions worth asking

  • Which indication and formulation does the source describe?
  • Does the video make a broader claim than the source supports?
  • Its short bowel syndrome context is different from GLP-1 appetite medicines.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Does a trial response mean patients no longer needed IV support?

Not necessarily. The response threshold was a reduction in support volume, not complete independence.

Source: MedlinePlus · Teduglutide ↗

Is GLP-2 simply another name for GLP-1?

No. They are different signaling pathways with different therapeutic aims.

Source: Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Teduglutide

Download illustration ↓Source record ↗
Teduglutide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.